- Home
- AIP vs LXRX Comparison
AIP vs LXRX Comparison
Compare AIP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- LXRX
- Stock Information
- Founded
- AIP 2003
- LXRX 1995
- Country
- AIP United States
- LXRX United States
- Employees
- AIP N/A
- LXRX N/A
- Industry
- AIP Semiconductors
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- AIP Technology
- LXRX Health Care
- Exchange
- AIP Nasdaq
- LXRX Nasdaq
- Market Cap
- AIP 579.6M
- LXRX 552.4M
- IPO Year
- AIP 2021
- LXRX 2000
- Fundamental
- Price
- AIP $13.85
- LXRX $1.41
- Analyst Decision
- AIP Strong Buy
- LXRX Buy
- Analyst Count
- AIP 3
- LXRX 5
- Target Price
- AIP $15.00
- LXRX $3.23
- AVG Volume (30 Days)
- AIP 871.5K
- LXRX 2.7M
- Earning Date
- AIP 11-05-2025
- LXRX 11-11-2025
- Dividend Yield
- AIP N/A
- LXRX N/A
- EPS Growth
- AIP N/A
- LXRX N/A
- EPS
- AIP N/A
- LXRX N/A
- Revenue
- AIP $63,236,000.00
- LXRX $58,432,000.00
- Revenue This Year
- AIP $19.05
- LXRX $66.55
- Revenue Next Year
- AIP $17.96
- LXRX N/A
- P/E Ratio
- AIP N/A
- LXRX N/A
- Revenue Growth
- AIP 18.64
- LXRX 1504.83
- 52 Week Low
- AIP $5.46
- LXRX $0.28
- 52 Week High
- AIP $14.88
- LXRX $2.08
- Technical
- Relative Strength Index (RSI)
- AIP 60.22
- LXRX 52.25
- Support Level
- AIP $12.35
- LXRX $1.36
- Resistance Level
- AIP $14.49
- LXRX $1.58
- Average True Range (ATR)
- AIP 1.18
- LXRX 0.11
- MACD
- AIP -0.04
- LXRX -0.02
- Stochastic Oscillator
- AIP 59.41
- LXRX 21.67
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.